tapebrief
REGN · Q3 2025
REGN · Q1 2026

REGN · Q4 2025 Earnings

Bullish

Regeneron Pharmaceuticals

Reported January 30, 2026

30-second summary

EYLEA HD U.S. ($506M, +66% YoY) closed the gap with branded EYLEA U.S. ($577M, -52% YoY) — on track to approach parity with EYLEA U.S. in coming quarters, with management noting HD now contributes "nearly half" of total U.S. retina net sales. Q4 revenue grew just 3% to $3.88B, but the real news is FY2026: management raised non-GAAP R&D guidance to $5.90–$6.10B (vs prior $5.10–$5.20B, a 13.5–19.6% lift) to fund 18 new Phase III starts and three new-molecular-entity filings, while non-GAAP gross margin guidance was cut 200–300bps to 83–84%. The setup is a credible bridge from the EYLEA cliff to a next-blockbuster wave, paid for with explicit near-term margin compression.

Headline numbers

EPS

Q4 FY2025

$11.44

Revenue

Q4 FY2025

$3.88B

+3.0% YoY

Gross margin

Q4 FY2025

81.0%

Operating margin

Q4 FY2025

22.6%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$3.88B+3.0%$3.75B+3.5%
EPS$11.44—$11.83-3.3%
Gross margin81.0%—82.0%-100bps
Operating margin22.6%—27.4%-480bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
EYLEA HD U.S. net sales Q1 2026 sequential growthQ1 FY2026High single-digit sequential demand growth anticipated—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
R&D expense (GAAP)
FY 2026
$5.660–$5.790 billion$6.450–$6.680 billion+$0.79–$0.89 billion (13.9–15.4% increase)Raised
R&D expense (non-GAAP)
FY 2026
$5.100–$5.200 billion$5.900–$6.100 billion+$0.70–$1.00 billion (13.5–19.6% increase)Raised
SG&A expense (GAAP)
FY 2026
$2.810–$2.940 billion$2.860–$3.040 billion+$0.05–$0.10 billion (1.8–3.6% increase)Raised
SG&A expense (non-GAAP)
FY 2026
$2.450–$2.550 billion$2.500–$2.650 billion+$0.05–$0.10 billion (2.0–4.1% increase)Raised
Gross margin on net product sales (GAAP)
FY 2026
Approximately 83%79%–80%-3 to -4 percentage pointsLowered
Gross margin on net product sales (non-GAAP)
FY 2026
Approximately 86%83%–84%-2 to -3 percentage pointsLowered
Cost of collaboration and contract manufacturing (COCM)
FY 2026
$1.000–$1.050 billion$940 million–$1.020 billion-$0.03 to +$0.02 billion (range tightened; midpoint -1.5%)Lowered
Capital expenditures
FY 2026
$880–$950 million$1.100–$1.300 billion+$0.15–$0.35 billion (16.3–41.7% increase)Raised
Effective tax rate (GAAP)
FY 2026
11%–13%12%–14%+1 percentage point (range shifted higher)Raised
Effective tax rate (non-GAAP)
FY 2026
11%–13%13%–15%+2 percentage points (range shifted higher)Raised

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
EYLEA HD U.S.$0.506B+66.0%
EYLEA U.S.$0.577B-52.0%
Dupixent (recorded by Sanofi)$4.94B+34.0%
Libtayo Global$0.425B+16.0%
Praluent U.S.$0.073B+16.0%
Sanofi collaboration revenue$1.64B+35.0%
Bayer collaboration revenue$0.319B-15.0%
EYLEA HD U.S. net sales YoY growth66%—
Dupixent global net sales YoY growth34%—
Libtayo global net sales YoY growth16%—

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Dupixent active patients worldwide1.4 million
Non-GAAP gross margin on net product sales85%
Non-GAAP operating margin~29%
Free cash flow$4.1 billion (FY)
Clinical pipeline candidates~45 in development

Management tone

Q2 (cautious): Catalent filling delays → Q4 (bullish): "I have never been more excited about the breadth, depth, and potential impact of our pipeline" (Chief Scientific Officer George Yancopoulos).

Two quarters ago the EYLEA HD story was hostage to a third-party filler; this quarter management framed it as the category leader with "the broadest label and greatest dosing flexibility of any anti-VEGF medicine" — citing real-world data that switchers extended treatment duration by "almost four weeks." The 2026 EYLEA HD pre-filled syringe approval is now treated as one of four expected FDA approvals rather than a contested PDUFA. The shift from defensive franchise commentary to confident category positioning is the single biggest tonal change since Q2.

Linvoseltamab (Lynozyfic) moved up the disease spectrum. In Q2, management positioned it as a late-line relapsed/refractory myeloma asset with smoldering-myeloma data as upside. This quarter management led with "linvoseltamab monotherapy achieved 100% MRT negativity in all 12 evaluable patients with high-risk smoldering myeloma, whereas the standard of care, daratumumab, achieved less than 10% in complete response." The framing is no longer "we'll build adoption in late line" — it is "best-in-class monotherapy across the disease spectrum." The 10-registrational-trial roadmap from Q2 now has the data to support investor underwriting.

Pipeline language hardened from broad-but-early to imminent-and-quantified. Q2 spoke about pipeline optionality without firm dates; this quarter management committed to "at least four FDA approvals, including three for new molecular entities across three distinct modalities" and "18 additional Phase III studies with cumulative target enrollment of approximately 35,000 patients" in 2026. The $800M+ R&D guide-up is the financial corroboration — management is putting cash behind the rhetoric, which is why we read the tone as conviction rather than narrative inflation.

Long-acting biologics moved from "future consideration" to immediate clinic. George said the "long-acting IL-13 antibody in atopic dermatitis is expected to enter the clinic in the coming months, embarking on an expedited development plan." This is the explicit Dupixent-extension answer the franchise has needed; it is now a near-term clinical reality rather than a slide-deck placeholder.

Recurring themes management leaned on this quarter:

Dupixent blockbuster durability and underpenetrated indications driving near/medium/long-term growthILEA-HD competitive moat through label breadth and durability advantages in crowded anti-VEGF categoryLinazivic transformational potential across myeloma disease spectrum from early-line through maintenanceImminent Phase III initiation surge (18 studies, 35,000 cumulative enrollment) positioning next blockbuster waveLong-acting antibody platform (IL-4, IL-13, IL-4/IL-13 bispecific) for next-generation immunology leadershipRare disease breakthroughs (gene therapy, FOP, PNH) demonstrating R&D excellence and orphan market optionality

Risks management surfaced:

ILEA 2mg biosimilar competition 'expected to intensify the second half of 2026 as multiple biosimilar products are launched in the United States'Anti-VEGF category declining approximately 12% in innovative branded segment in 2025Patient affordability/co-pay issues 'that have dampened branded anti-VEGF category growth' despite $200 million matching donation commitmentWholesaler inventory elevation of approximately $30 million at end of Q4 for ILEA-HD and ILEA expected to negatively impact Q1 2026Federal cost negotiation uncertainties requiring 'constructive discussions with the Center for Medicare and Medicaid Services'

Q&A highlights

Alexandria Hammond · Wolf Research

Timing of Liptile plus Finelimab readouts in metastatic melanoma and adjuvant melanoma settings, and whether interim updates will coincide.

Management stated first half is the best estimate for advanced melanoma readout. Adjuvant timing is also first half; interim readouts may or may not coincide, with data to be released shortly after availability.

Advanced melanoma readout: first half timeframeAdjuvant readout: first half timeframeInterim readouts may or may not coincide

Salvin Richter · Goldman Sachs

Guidance on hazard ratio expectations for frontline metastatic melanoma study and PD-L1 expression levels of enrolled patients.

Study is powered for primary endpoint (PFS) at level of current standard of care, with hope to achieve better. Study also powered for overall survival benefit. PD-L1 expression not used as inclusion/exclusion criteria; population expected to represent true first-line advanced melanoma patients.

Primary endpoint: PFS at current standard of care levelPowered for overall survival benefitTwo dose groups in studyNo PD-L1 floor or cap; unselected population

Tazeen Ahmad · Bank of America

Geographic atrophy program differentiation versus approved competitors; whether visual acuity benefit is required versus slowing vision loss with better safety.

Management expects more profound blockade via antibodies/SRNAs versus aptamer/pegylated approaches used by competitors. Systemic approach avoids local blinding risks (retinal vasculitis) from current therapies. Testing both syndicerine monotherapy and combination approach. Primary endpoint is GA lesion growth rate; prospective secondary endpoint measures 15-letter loss in visual acuity at year 1 and 2.

Primary endpoint: GA lesion growth rateProspective secondary endpoint: 15-letter visual acuity loss at year 1 and 2Systemic approach avoids retinal vasculitis risksTesting monotherapy and combination approaches

Jeff Meacham · Citi

ILEA-HD growth trends for 2025-2026, sources of growth (new patients vs. switches), and pre-filled syringe impact as potential gating factor.

Good progress with ILEA-HD in marketplace. Recent label enhancements (Q4 weekly dosing, RVO) well-received. Pre-filled syringe will be convenience factor and new opportunity, though many current users exist.

Q4 weekly dosing recently approved and well-receivedRVO indication recently added and well-receivedPre-filled syringe pending approval; characterized as convenience enhancement

Evan Seegerman · BMO Capital Markets

Confidence rationale for moving GLP-1/GIP combo into global Phase III trials given rapid market evolution, and differentiation versus standard of care and competing assets.

Core differentiation is co-formulation with PCSK9 inhibitor in single syringe; addresses 50%+ of obese patients with high cholesterol. Asset already extensively studied in China; tirazepatide-like efficacy/safety profile. Commercial strategy is not direct weight-loss competition but combination benefits. Phase III trials already advanced in China.

Co-formulation with PCSK9 in single autoinjector at same dosing interval50-60% LDL lowering with single combinationTirazepatide-like efficacy and safety profileAdvanced Phase III trials ongoing in China

Answers to last quarter's watch list

Catalent filling resolution and revised EYLEA HD PDUFA dates — Effectively resolved. Management now lists the EYLEA HD pre-filled syringe approval among four expected FDA approvals in 2026, and every-4-week (monthly) dosing plus RVO label additions are in hand.
Resolved positively
EYLEA + EYLEA HD U.S. combined revenue trajectory — Q4 combined U.S. retina was $1.083B, down ~23% YoY, marginally better than Q2's -25%. EYLEA HD (+66%) now contributes nearly half of the combined franchise, but management guided Q1 to high-single-digit sequential HD growth offset by double-digit EYLEA U.S. demand decline plus a ~$30M inventory headwind. Stabilization is not yet here.
Continue monitoring
Branded anti-VEGF segment dynamics — The branded anti-VEGF category declined ~12% in 2025 per management, a sharper erosion than the 1.2% volume shrink cited in Q2. Regeneron did not re-quote a category share figure on this print. Aflibercept 2mg biosimilar launches in 2H26 will compound the pressure.
Resolved negatively
Libtayo adjuvant CSCC approval (October 2025 PDUFA) — Cleared; adjuvant CSCC is now in the launched label and Libtayo grew 16% YoY to $425M. The next catalyst is the first-half-2026 fianlimab combo readout in advanced and adjuvant melanoma.
Resolved positively
Linvoseltamab myeloma readouts and Phase III pace — Major positive update: 100% MRT negativity in 12/12 high-risk smoldering myeloma patients on monotherapy vs <10% CR for daratumumab; 9/9 evaluable newly-diagnosed patients hit MRT-negativity. Linvoseltamab is now framed as cross-spectrum best-in-class, not late-line salvage.
Resolved positively
Itepekimab COPD path — Not addressed on this print's available materials. The pipeline narrative pivoted toward long-acting IL-13 antibody entering the clinic "in the coming months" as the next-gen immunology bet, suggesting IL-33 in COPD has been de-prioritized without explicit termination.
Continue monitoring

What to watch into next quarter

EYLEA HD trajectory and Q1 combined U.S. retina print — with management guiding high-single-digit HD sequential demand growth and double-digit EYLEA U.S. demand decline plus a ~$30M Q1 inventory drag, watch whether combined U.S. retina holds above the $1.0B line and how quickly HD's share of the combined franchise advances past the "nearly half" mark management cited.

Aflibercept 2mg biosimilar timing detail for 2H26 — management flagged "multiple biosimilar products" launching in the U.S. in 2H26. Any sharpening of launch dates or projected discount levels in Q1 commentary will move the combined-franchise terminal value.

Non-GAAP gross margin actuals vs the new 83–84% guide — Q4 GAAP net product gross margin was 81% and FY was 82%. Watch whether Q1 prints inside the new band or whether the cut understates the mix pressure from EYLEA U.S. erosion and COCM.

Linvoseltamab Phase III initiation pace — management's 18-Phase-III roadmap and the smoldering-myeloma vs daratumumab dataset raise the bar; watch how many of the linvoseltamab registrational trials initiate in 1H26 against the 10-trial myeloma target laid out in Q2.

Fianlimab + Libtayo melanoma readouts (1H26) — both advanced and adjuvant readouts due first half. The bar set in Q&A — PFS powered at current standard-of-care level with hoped-for upside, plus OS powering — frames a binary on a near-term blockbuster candidate.

R&D burn cadence against the $5.9–$6.1B non-GAAP guide — with the floor lifted ~$800M, Q1 R&D as a percent of revenue will set the credibility of the "spending to convert pipeline" narrative. A Q1 print materially above guide-implied run-rate (~$1.5B/quarter) without commensurate Phase III start visibility would be a yellow flag.

Sources

  1. Regeneron Q4 2025 press release (Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm
  2. Regeneron Q4 2025 earnings call commentary
  3. Tapebrief Q2 2025 REGN brief (prior watch list and trend context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.